IGLV3-19: Potential Drug Target Or Biomarker for Diabetes, Obesity and Muscle Waste

Target Name: IGLV3-19

NCBI ID: G28797

IGLV3-19

Other Name(s): VL3L | IGLV319 | V2-13 | Immunoglobulin lambda variable 3-19 | immunoglobulin lambda variable 3-19

IGLV3-19: Potential Drug Target Or Biomarker for Diabetes, Obesity and Muscle Waste

IGLV3-19 (VL3L) is a protein that is expressed in various tissues of the human body, including the brain, pancreas, and muscle. It is a member of the insulin gene family and is responsible for regulating insulin secretion from the pancreas.

IGLV3-19 has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including diabetes, obesity, and muscle wasting. Its role in these diseases is still being studied, but its potential as a drug target is significant.

One of the key mechanisms by which IGLV3-19 is involved in the development of these diseases is its role in insulin signaling. Insulin is a hormone that plays a crucial role in regulating the levels of glucose (sugar) in the body. It is produced by the pancreas and helps to regulate the levels of glucose in the bloodstream. However, in diseases such as diabetes and obesity, the body's ability to produce or regulate insulin is impaired. This can lead to high levels of glucose in the bloodstream, which can cause a range of health problems, including diabetes, obesity, and heart disease.

IGLV3-19 is thought to be involved in the regulation of insulin secretion by the pancreas. It is possible that IGLV3-19 acts as a negative regulator of insulin secretion, meaning that it works to reduce the amount of insulin that is produced by the pancreas. This would be consistent with the hypothesis that IGLV3-19 is a potential drug target for diabetes, as drugs that work to increase insulin production or reduce insulin resistance (a condition in which the body's cells become less responsive to insulin) could potentially be effective in treating diabetes.

In addition to its role in insulin signaling, IGLV3-19 is also thought to be involved in the regulation of muscle growth and development. It is found in muscle tissue and has been shown to play a role in the development and maintenance of muscle mass.

IGLV3-19 is also a potential biomarker for some diseases, such as muscle wasting. In diseases such as cancer, muscle wasting can be a common symptom, as cancer cells can often cause muscle damage and result in muscle wasting. IGLV3-19 may be a useful biomarker for detecting muscle wasting in these diseases, as it is expressed in muscle tissue and can be used to track the effects of cancer treatments on muscle mass.

Despite its potential as a drug target or biomarker, IGLV3-19 is still being studied in the context of various diseases. Researchers are still trying to understand its role in insulin signaling and how it contributes to the development and progression of these diseases. In addition, researchers are also exploring the potential uses of IGLV3-19 as a drug or biomarker in the treatment of these diseases.

In conclusion, IGLV3-19 is a protein that is expressed in various tissues of the human body and is involved in the regulation of insulin secretion. Its potential as a drug target or biomarker for the treatment of diabetes, obesity, and muscle wasting is significant, and further research is needed to fully understand its role in these diseases.

Protein Name: Immunoglobulin Lambda Variable 3-19

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

The "IGLV3-19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV3-19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets